diabetestalk.net

Metformin Liver Toxicity

Continuation Of Metformin Use After A Diagnosis Of Cirrhosis Significantly Improves Survival Of Patients With Diabetes

Continuation Of Metformin Use After A Diagnosis Of Cirrhosis Significantly Improves Survival Of Patients With Diabetes

Abstract The risks and benefits of metformin use in patients with cirrhosis with diabetes are debated. Although data on a protective effect of metformin against liver cancer development have been reported, metformin is frequently discontinued once cirrhosis is diagnosed because of concerns about an increased risk of adverse effects of metformin in patients with liver impairment. This study investigated whether continuation of metformin after cirrhosis diagnosis improves survival of patients with diabetes. Diabetic patients diagnosed with cirrhosis between 2000 and 2010 who were on metformin at the time of cirrhosis diagnosis were identified (n = 250). Data were retrospectively abstracted from the medical record. Survival of patients who continued versus discontinued metformin after cirrhosis diagnosis was compared using the log-rank test. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using Cox's proportional hazards analysis. Overall, 172 patients continued metformin whereas 78 discontinued metformin. Patients who continued metformin had a significantly longer median survival than those who discontinued metformin (11.8 vs. 5.6 years overall, P < 0.0001; 11.8 vs. 6.0 years for Child A patients, P = 0.006; and 7.7 vs. 3.5 years for Child B/C patients, P = 0.04, respectively). After adjusting for other variables, continuation of metformin remained an independent predictor of better survival, with an HR of 0.43 (95% CI: 0.24-0.78; P = 0.005). No patients developed metformin-associated lactic acidosis during follow-up. Conclusion: Continuation of metformin after cirrhosis diagnosis reduced the risk of death by 57%. Metformin should therefore be continued in diabetic patients with cirrhosis if there is no specific contraindication. (Hepatology 2014;60:200 Continue reading >>

Protective Effect Of Metformin On Cardiac And Hepatic Toxicity Induced By Adriamycin In Swiss Albino Mice

Protective Effect Of Metformin On Cardiac And Hepatic Toxicity Induced By Adriamycin In Swiss Albino Mice

Protective Effect of Metformin on Cardiac and Hepatic Toxicity Induced by Adriamycin in Swiss Albino Mice Diabetes Mellitus (DM) is a chronic disease that is characterized by deterioration of glycemic control. The disease is known to be caused by imbalance between Reactive Oxygen Species (ROS) and antioxidant defense systems. Hyperglycemia is commonly observed in a wide variety of diseases, including cancer. Although, therapy against glycemic control is used in all these diseases, the diabetic cancer patients are on additional therapy with anticancer drugs. The objective of present study was to investigate if metformin, a very popular antidiabetic agent can avert the cardiac and hepatic toxicity caused by Adriamycin (ADR), which is a commonly used cytotoxic drug. The experimental protocol included oral treatment of mice with different doses (62.5, 125 and 250 mg kg-1 day-1) of metformin for 7 days. Some mice in each group were injected i.p. with ADR (15 mg kg-1), 24 h prior to sacrifice. In each case animals were killed, 24 h after the last treatment, blood sample was collected and plasma was separated for analysis of AST, ALT and CK-MB. Liver and heart from the same animals were excised for analysis of proteins, nucleic acids, MDA and NP-SH. The results obtained revealed that pretreatment with metformin (i) reduced the ADR-induced increase in the concentrations of AST, ALT and CK-MB (ii) protected against the ADR-induced increase of MDA and decrease of DNA and NP-SH in both cardiac and hepatic tissues. These results demonstrate that the treatment with metformin might be useful to protect cardiac and hepatic toxicity. The exact mechanism of action is not known, however; the inhibition of ADR-induced increase of plasma enzymes and MDA and depletion of DNA and NP-SH by m Continue reading >>

The Effect Of Metformin On Liver Function Tests In The Diabetes Prevention Program

The Effect Of Metformin On Liver Function Tests In The Diabetes Prevention Program

The Effect of Metformin on Liver Function Tests in the Diabetes Prevention Program Metformin may lower aminotrans Metformin may lower aminotransferase concentrations in non-alcoholic fatty liver disease (NAFLD), which is common in people with type 2 diabetes, obesity and/or insulin resistance. In the Diabetes Prevention Program (DPP), 2153 adults with impaired glucose tolerance, an overweight group likely to be at high risk for NAFLD, were randomized to metformin (MET; n=1072) or placebo (PLAC; n=1081) between 1996 and 1999 and followed for an average of 3.2 years. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured at baseline, 3 and 6 months and every 6 months thereafter. Regression models controlling for co-variates and repeated measures were used to evaluate the effect of metformin on AST or ALT in the whole group and a sub-group reporting no alcohol use at baseline. Incidence of development of abnormal AST or ALT was calculated using sex-specific NHANES III 95th percentile for AST and ALT among participants below those cut-offs at baseline. AST and ALT were lower in the MET vs. PLAC groups (geometric means averaged over time for AST, 21.7 vs. 22.2 U/l, p=0.03; for ALT, 19.3 vs. 20.1 U/l, p=0.004) and remained so after adjustment for age, sex, BMI, fasting glucose and insulin at baseline (adjusted geometric means averaged over time (for AST, 22.1 vs. 22.6 U/l, p=0.02; for ALT, 19.7 vs. 20.7 U/l, p=0.001). ALT (but not AST) remained significantly lower in the MET group after separate adjustment for glucose and insulin at each visit, but not after separate adjustment for weight loss (19.5 vs. 20.3 U/l, p=0.2), indicating the effect on ALT is mediated via weight loss. In the sub-group with no alcohol use at baseline, ALT was significantly Continue reading >>

Metformin, The Liver, And Diabetes

Metformin, The Liver, And Diabetes

Most people think diabetes comes from pancreas damage, due to autoimmune problems or insulin resistance. But for many people diagnosed “Type 2,” the big problems are in the liver. What are these problems, and what can we do about them? First, some basic physiology you may already know. The liver is one of the most complicated organs in the body, and possibly the least understood. It plays a huge role in handling sugars and starches, making sure our bodies have enough fuel to function. When there’s a lot of sugar in the system, it stores some of the excess in a storage form of carbohydrate called glycogen. When blood sugar levels get low, as in times of hunger or at night, it converts some of the glycogen to glucose and makes it available for the body to use. Easy to say, but how does the liver know what to do and when to do it? Scientists have found a “molecular switch” called CRTC2 that controls this process. When the CRTC2 switch is on, the liver pours sugar into the system. When there’s enough sugar circulating, CRTC2 should be turned off. The turnoff signal is thought to be insulin. This may be an oversimplification, though. According to Salk Institute researchers quoted on RxPG news, “In many patients with type II diabetes, CRTC2 no longer responds to rising insulin levels, and as a result, the liver acts like a sugar factory on overtime, churning out glucose [day and night], even when blood sugar levels are high.” Because of this, the “average” person with Type 2 diabetes has three times the normal rate of glucose production by the liver, according to a Diabetes Care article. Diabetes Self-Management reader Jim Snell brought the whole “leaky liver” phenomenon to my attention. He has frequently posted here about his own struggles with soarin Continue reading >>

Metformin Liver Toxicity Bile Reflux

Metformin Liver Toxicity Bile Reflux

You should stop a statin if you develop liver disease. Autoimmune hepatitis is typically chronic meaning it can last for years and can lead to cirrhosisscarring and hardeningof the liver. Metformin Liver Toxicity Bile Reflux allergy drugs such as fexofenadine (Allegra). Milk thistle is a plant thats native to the most notably a group of chemical compounds referred to as silymarin. Prolonged blockage of a bile duct can cause a buildup of waste products in the biliary tract and in the If a stone completely blocks milk thistle pills liver scan ultrasound bright the ducts of the gallbladder liver common bile duct or pancreas other However this is a rare disease and most people with gallstones do not go on to develop cancer. Gaspari Max Mass Stack. Modulation of programmed cell death by medicinal milk thistle yellow dock supreme test sgpt symptoms function plants. Directions TO APPLY: Peel and take two pills after you just slap this patch on your wrist and you do not have to worry about how much you consume or having to take additional pills later. Note that vegetarian diets are sometimes recommended. Milk thistle will rid liver of harmful element traces and help restore liver cell function. Metastatic liver cancer starts somewhere else in the body and metastasizes (spreads) to the liver. The recovery in the hospital averages five days. lactulose chronic liver disease. Fluid retention; coughs; fear; thymus gland; calms nerves; problems with eyes ears jaw neck stomach teeth; mental clarity; meditation. Juice So Good is more than a juice bar were a non-gmo plant-based grab-and-go and: offering cold-pressed juices cleanses smoothies and superfood options. Liver disease (also called hepatic (autoimmune hepatitis) or hereditary conditions. Having hemochromatosis an iron storage Continue reading >>

Clarifying Metformin's Role And Risks In Liver Dysfunction.

Clarifying Metformin's Role And Risks In Liver Dysfunction.

Abstract OBJECTIVES: To explore why some clinicians hesitate to use metformin in patients with liver disease and whether routine monitoring of transaminases before and during metformin therapy is substantiated. DATA SOURCES: A Medline literature search was conducted (1966 to June 2008) using the terms metformin, lactic acidosis, liver disease, chronic liver disease, hepatotoxicity, hypoxia, risks, and predisposing factors. DATA SYNTHESIS: Manufacturer prescribing information and some current medical and lay press literature caution against metformin use in patients with liver disease. This recommendation is interpreted variably by different prescribers, with some believing that the caution implies metformin can cause or worsen liver injury. Others believe that liver disease predisposes patients to developing lactic acidosis. A clearer understanding of how and when to screen for liver dysfunction in patients before and during metformin therapy is thus warranted. CONCLUSION: Metformin does not appear to cause or exacerbate liver injury and, indeed, is often beneficial in patients with nonalcoholic fatty liver disease. Nonalcoholic fatty liver frequently presents with transaminase elevations but should not be considered a contraindication to metformin use. Literature evidence of liver disease being associated with metformin-associated metabolic acidosis is largely represented by case reports. Most such patients had cirrhosis and were also actively using alcohol. Patients with cirrhosis, particularly those with encephalopathy, may have arterial hypoxemia, which heightens the risk of developing lactic acidosis. For this reason, identifying patients with cirrhosis before initiating metformin seems prudent. Because cirrhosis can exist in the face of normal liver transaminases, Continue reading >>

A Rare Outcome Induced By Metformin Intoxication: Severe Lactic Acidosis And Hepatotoxicity

A Rare Outcome Induced By Metformin Intoxication: Severe Lactic Acidosis And Hepatotoxicity

1. Aksay E, Yanturali S, Bayram B, et al. A Rare Side Effect of Metformin: Metformin-Induced Hepatotoxicity. Turk J Med Sci 2007; 37 (3): 173-175. 2. Giuliani E, Albertini G, Vaccari C, Barbieri A. pH 6.68-surviving severe metformin intoxication. Q J Med 2010; 103: 887-890. 3. Sencan A, Adanir T, Atay A, et al. High Anion Gap Metabolic acidosis after Suicide: Metformn ntoxication. Anesthesia Journal 2011; 19 (1): 56-59. 4. Heaney D, Majid A and Junor B. Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 1997; 12: 1046-1047. 5. Perincek G, Edis EC, Guldiken S, Uyanik MS. A Rare Outcome Induced by Metformin Intoxication: Severe Lactic Acidosis and Sudden Cardiac Arrest. Kartal Training and Research Medicine Journal 2009; XX(1): 42-44. 6. Zheng L. Metformin as a Rare Cause of Drug-Induced Liver Injury, a Case Report and Literature Review. Am J Ther 2016; 23(1): e315-e317. 7. Nammour FE1, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocr Pract 2003; 9(4): 307-309. 8. Hashmi T. Probable hepatotoxicity associated with the use of metformin in type 2 diabetes. BMJ Case Rep 2011; 2011. pii: bcr0420114092. 9. Saadi T1, Waterman M, Yassin H, Baruch Y. Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. Int J Gen Med 2013; 6: 703-706. 10. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978; 24: 683-693. 11. Desilets DJ, Shorr AF, Moran KA, Holtzmuller KC. Cholestatic jaundice associated with the use of metformin. Am J Gastroenterol 2001; 96: 2257-2258. 12. Akinci B, Yener S, Bengi G, Yesil S. Alterations of coagulation in metformin intoxication. Hormones 2008; 7(4): 325-329. 13. Packer CD, Hor Continue reading >>

Metformin-induced Hepatotoxicity

Metformin-induced Hepatotoxicity

Metformin is the first choice oral antidiabetic drug for type 2 diabetes and currently the most consumed. Although gastrointestinal intolerance is frequent, metformin-induced hepatotoxicity is rare. Fewer than 10 cases have been reported (1). In all of those cases, metformin was associated with concomitant intake of other potentially hepatotoxic drugs. We present what we feel may be the first documented case of hepatotoxicity due to metformin with no other drug interference. A 61-year-old man was admitted to the hospital with a 3-day history of painless jaundice. He had no history of liver disease or toxic habits and denied previous consumption of drugs or herbal products, but had been taking metformin (1,700 mg/day for 6 weeks) after being diagnosed with type 2 diabetes. Laboratory tests showed a mixed pattern of liver damage (total bilirubin 2.9 mg/dL, direct bilirubin 2.4 mg/dL, aspartate aminotransferase [AST] 290 units/L [≤40], alanine aminotransferase [ALT] 861 units/L [≤35], γ-glutamyltransferase [GGT] 861 units/L [≤35], and alkaline phosphatase [ALP] 622 units/L [≤120]). International normalized ratio and eosinophil counts were normal. Diagnostic work-up ruled out viral hepatitis A, B, and C, as well as autoimmune and metabolic liver disease (negative antinuclear antibodies, anti-mitochondrial antibodies, smooth muscle antibodies, anti-liver/kidney microsomal antibodies; normal ceruloplasmin, α-1 antitrypsin, copper). Abdominal ultrasound and cholangio-MRI showed no pathological findings. The patient refused a liver biopsy. After stopping metformin, the patient's clinical condition progressively improved and liver enzymes normalized in 30 days. He was discharged with only recommendations to modify his lifestyle. Six weeks after discharge, the patient a Continue reading >>

The Liver Disease Epidemic You Need To Know About

The Liver Disease Epidemic You Need To Know About

Extracts of milk thistle have long been used for liver protection. It is estimated that 30-40% of American liver disease patients use the active ingredient, silymarin.60 Silymarin is itself composed of six major active molecules such as silybin, which are known as flavolignans, with exceptional antioxidant and anti-inflammatory activity.60,61 Modern science is rediscovering the use of milk thistle extracts for reduction of the impact of NAFLD and preventing its progression to NASH. One very effective combination is silymarin plus vitamin E and phospholipids (such as phosphatidylcholine); this approach improves the overall antioxidant activity of the compound.62 In animal studies the combination limited liver depletion of the natural antioxidant glutathione, and reduced mitochondrial stress damage.63 Human trials have shown that a preparation providing 376 mg silybin, 776 mg phosphatidylcholine, and 360 mg vitamin E produces therapeutic effects in patients with a variety of different forms of liver damage, improving insulin resistance, reducing liver fat accumulation, and reducing blood levels of markers of liver scarring.22,23,64 Open studies have shown that silymarin also significantly increased survival rates in patients with alcohol-induced liver cirrhosis.61 Phospholipids—fat molecules with phosphate groups attached—are major constituents of cell membranes in mammals.65 One of the most important phospholipids in humans is phosphatidylcholine (PC), which is available in small amounts in the diet. Higher ratios of PC to other phospholipids in cell membranes help to assure membrane integrity in the face of oxidative and other stresses; they also help limit the progression of NAFLD into NASH.65 A particularly rich source of PC molecules is a mixture called polyenyl Continue reading >>

The Liver Disease Epidemic You Need To Know About

The Liver Disease Epidemic You Need To Know About

Metformin Because of the central role of insulin resistance in development of NAFLD and NASH, it makes sense to evaluate insulin-sensitizing drugs for their prevention.36,37 No oral antidiabetic drug has as broad a spectrum of action, and as hefty a safety record, as the drug metformin, which is finding a host of new applications outside of diabetes itself.38,39 Studies of metformin for NAFLD and NASH have multiplied in the past few years with almost uniform success. Metformin in the amount of 500 mg three times daily for 6 months produced dramatic improvements in liver blood flow and velocity as detected by Doppler ultrasound exams.40 A similar dose of metformin (20 mg/kg body weight for one year, or approximately 1,450 mg/day for a 160-pound person) produced reductions in blood markers of liver cell death, though the improvement lasted only 3 months.41 On the other hand, improved insulin sensitivity has repeatedly been shown in patients with NASH and NAFLD who take metformin, and many studies have now shown sustainable improvements in liver chemistry measurements.36,42 And a recent study showed significant reduction in the prevalence and severity of fatty liver after 6 months’ treatment with 850 mg metformin twice daily in obese adolescents, an extremely challenging group of patients.43 Metformin is an ideal drug for combination studies because of its safety and compatibility with other therapies. A 2008 study revealed that the combination of metformin with the potent antioxidant N-acetyl cysteine (NAC) for 12 months improved both liver chemistry results and measurements of insulin resistance.44 Liver tissue evaluated by biopsy also showed improved appearance for the earlier signs of disease. Finally, in 2010 we learned of an entirely new mechanism by which metformi Continue reading >>

Metformin (glucophage) Side Effects & Complications

Metformin (glucophage) Side Effects & Complications

The fascinating compound called metformin was discovered nearly a century ago. Scientists realized that it could lower blood sugar in an animal model (rabbits) as early as 1929, but it wasn’t until the late 1950s that a French researcher came up with the name Glucophage (roughly translated as glucose eater). The FDA gave metformin (Glucophage) the green light for the treatment of type 2 diabetes in 1994, 36 years after it had been approved for this use in Britain. Uses of Generic Metformin: Glucophage lost its patent protection in the U.S. in 2002 and now most prescriptions are filled with generic metformin. This drug is recognized as a first line treatment to control blood sugar by improving the cells’ response to insulin and reducing the amount of sugar that the liver makes. Unlike some other oral diabetes drugs, it doesn’t lead to weight gain and may even help people get their weight under control. Starting early in 2000, sales of metformin (Glucophage) were challenged by a new class of diabetes drugs. First Avandia and then Actos challenged metformin for leadership in diabetes treatment. Avandia later lost its luster because it was linked to heart attacks and strokes. Sales of this drug are now miniscule because of tight FDA regulations. Actos is coming under increasing scrutiny as well. The drug has been banned in France and Germany because of a link to bladder cancer. The FDA has also required Actos to carry its strictest black box warning about an increased risk of congestive heart failure brought on by the drug. Newer diabetes drugs like liraglutide (Victoza), saxagliptin (Onglyza) and sitagliptin (Januvia) have become very successful. But metformin remains a mainstay of diabetes treatment. It is prescribed on its own or sometimes combined with the newer d Continue reading >>

Protective Effect Of Metformin On Toxicity Of Butyric Acid And Arsenic In Isolated Liver Mitochondria And Langerhans Islets In Male Mice: An In Vitro Study

Protective Effect Of Metformin On Toxicity Of Butyric Acid And Arsenic In Isolated Liver Mitochondria And Langerhans Islets In Male Mice: An In Vitro Study

Ahangarpour, A., zeidooni, L., Rezaei, M., Alboghobeish, S., samimi, A., Oroojan, A. (2017). Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an in vitro study. Iranian Journal of Basic Medical Sciences, 20(12), 1297-1305. doi: 10.22038/ijbms.2017.9567 Akram Ahangarpour; Leila zeidooni; Mohsen Rezaei; Soheila Alboghobeish; Azin samimi; Ali Akbar Oroojan. "Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an in vitro study". Iranian Journal of Basic Medical Sciences, 20, 12, 2017, 1297-1305. doi: 10.22038/ijbms.2017.9567 Ahangarpour, A., zeidooni, L., Rezaei, M., Alboghobeish, S., samimi, A., Oroojan, A. (2017). 'Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an in vitro study', Iranian Journal of Basic Medical Sciences, 20(12), pp. 1297-1305. doi: 10.22038/ijbms.2017.9567 Ahangarpour, A., zeidooni, L., Rezaei, M., Alboghobeish, S., samimi, A., Oroojan, A. Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an in vitro study. Iranian Journal of Basic Medical Sciences, 2017; 20(12): 1297-1305. doi: 10.22038/ijbms.2017.9567 Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an in vitro study 2 ; Mohsen Rezaei 3 ; Soheila Alboghobeish 4 ; Azin samimi 2 ; Ali Akbar Oroojan 5 1Health Research Institute, Diabetes Research Center, Department of Physiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 2Department of Toxicology, Continue reading >>

Metformin Ameliorates Arsenic Trioxide Hepatotoxicity Via Inhibiting Mitochondrial Complex I

Metformin Ameliorates Arsenic Trioxide Hepatotoxicity Via Inhibiting Mitochondrial Complex I

Cell Death & Disease volume 8, page e3159 (2017) Arsenic trioxide (ATO) is a well-accepted chemotherapy agent in managing promyelocytic leukemia. ATO often causes severe health hazards such as hepatotoxicity, dermatosis, neurotoxicity, nephrotoxicity and cardiotoxicity. The production of reactive oxygen species, (ROS) play a significant role in ATO-induced hepatotoxicity. The oral hypoglycemic drug, metformin, is considered to be a potential novel agent for chemoprevention in the treatment of cancer. Moreover, metformin has also been shown to have hepatoprotective effects. In the present study, we demonstrated that metformin protected normal hepatocytes from ATO-induced apoptotic cell death in vitro and in vivo. Gene expression screening revealed that glucose metabolism might be related to the metformin-induced protective effect on ATO-treated AML12 cells. The metformin-promoted or induced glycolysis was not responsible for the protection of AML12 cells from ATO-induced apoptotic cell death. Instead, metformin increased the intracellular NADH/NAD+ ratio by inhibiting mitochondrial respiratory chain complex I, further decreasing the intracellular ROS induced by ATO. Treatment with low glucose or rotenone, a mitochondrial respiratory chain complex I inhibitor, also protected AML12 cells from ATO-induced apoptotic cell death. We show for the first time that metformin protects the hepatocyte from ATO by regulating the mitochondrial function. With its properties of chemoprevention, chemosensitization and the amelioration of liver damage, metformin has great prospects for clinical application other than type 2 diabetes mellitus (T2DM). Arsenic trioxide (As2O3, ATO) has long been used as a therapeutic agent for certain severe diseases including malaria, syphilis, leukemia, tu Continue reading >>

Metformin Effects On The Liver

Metformin Effects On The Liver

Physicians commonly prescribe Metformin if you have Type 2 diabetes and need help controlling your blood sugar. It reduces how much glucose you absorb from food and the amount your liver produces. On rare occasions, however, Metformin causes liver dysfunction and a serious metabolic condition involving the liver. For this reason, physicians exercise caution when prescribing Metformin to patients with liver disease. Video of the Day In healthy individuals, the liver produces glucose to keep blood sugar stable when you haven't eaten for several hours. Uncontrolled glucose production in the liver may cause high blood sugar in individuals with Type 2 diabetes. Researchers discovered that Metformin blocks critical enzymes involved in signaling the liver to produce glucose, thereby decreasing blood sugar levels. Their work was reported in the February 2013 edition of the journal "Nature." Lactic Acid Production Your muscles, brain, skin and other tissues produce a substance called lactic acid. Under normal circumstances, your liver and kidneys remove lactic acid from the blood and convert some of it to glucose. If a life-threatening metabolic condition known as lactic acidosis occurs, lactic acid levels increase faster than the liver can keep up with. Though its mechanism is unclear, Metformin causes lactic acidosis in a small segment -- up to 1 percent -- of patients, according to NYU Langone Medical Center. Almost all reported cases occurred in patients with underlying metabolic issues, such as liver or kidney disease. According to LiverTox, a publication of the U.S. National Library of Science drug database, Metformin may occasionally cause mild liver toxicity, characterized by minor elevations in liver enzymes. It occurs in less than 1 percent of the patients taking Metfo Continue reading >>

Metformin

Metformin

Metformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes,[4][5] particularly in people who are overweight.[6] It is also used in the treatment of polycystic ovary syndrome.[4] Limited evidence suggests metformin may prevent the cardiovascular disease and cancer complications of diabetes.[7][8] It is not associated with weight gain.[8] It is taken by mouth.[4] Metformin is generally well tolerated.[9] Common side effects include diarrhea, nausea and abdominal pain.[4] It has a low risk of causing low blood sugar.[4] High blood lactic acid level is a concern if the medication is prescribed inappropriately and in overly large doses.[10] It should not be used in those with significant liver disease or kidney problems.[4] While no clear harm comes from use during pregnancy, insulin is generally preferred for gestational diabetes.[4][11] Metformin is in the biguanide class.[4] It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues.[4] Metformin was discovered in 1922.[12] French physician Jean Sterne began study in humans in the 1950s.[12] It was introduced as a medication in France in 1957 and the United States in 1995.[4][13] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[14] Metformin is believed to be the most widely used medication for diabetes which is taken by mouth.[12] It is available as a generic medication.[4] The wholesale price in the developed world is between 0.21 and 5.55 USD per month as of 2014.[15] In the United States, it costs 5 to 25 USD per month.[4] Medical uses[edit] Metformin is primarily used for type 2 diabetes, but is increasingly be Continue reading >>

More in ketosis